Activities of the NCRI and UK lymphoma studies

ESH eLearning, Graham Collins, 202164

European Mantle Cell Network

ESH eLearning, Martin Dreyling, 202163

New generation studies in follicular and mantle cell lymphoma in the US National Clinical Trials Network (NCTN)

ESH eLearning, Little Richard, 202162

Novel inhibitors in lymphoma – an outlook

ESH eLearning, Carsten Niemann, 202161

Targeting BTK in current therapy of indolent NHL and CLL

ESH eLearning, Maddocks Kami J., 202160

BCL2 & regulation of the apoptotic response in lymphoid

ESH eLearning, Letai Anthony, 202159

Immune checkpoint inhibitors in indolent lymphomas

ESH eLearning, Stephen Ansell, 202158

Status of allogeneic transplant immunotherapy compared to CAR T cells (a comparative analysis)

ESH eLearning, David MALONEY, 202157

Initial diagnostic work up of MCL

ESH eLearning, Martin Dreyling, 202156

MRD in CLL

ESH eLearning, Andy Rawstron, 202155

Potential disparities in Europe

ESH eLearning, Michael Hallek, 202154

Disparity of lymphoma treatment in South America

ESH eLearning, Gabus Raul, 202153

Epigenetic basis of germinal center derived B Cell lymphomas

ESH eLearning, Ari Melnick, 202152

Modulation of the TME in NHL

ESH eLearning, Adrian Wiestner, 202151

CLL microenvironment as a drug target for kinase inhibitors

ESH eLearning, Jan Burger, 202150

Next generation sequencing data analysis: critical issues

ESH eLearning, Christian REINHARDT, 202149

Routes of transformation of follicular lymphoma

ESH eLearning, Jude FITZGIBBON, 202148

Genomic landscape of CLL and other indolent lymphoma

ESH eLearning, Catherine Wu, 202147

Later on ?

ESH eLearning, Philippe Moreau, 188660

From the start ?

ESH eLearning, Bart Barlogie, 188659

Amyloidosis: from proteomics to resolving proteins

ESH eLearning, GIAMPAOLO MERLINI, 188658

Treatment of Castleman: monoclonal antibodies or chemotherapy ?

ESH eLearning, Angela Dispenzieri, 188657

No treatment is no option for plasma cell leukaemia?

ESH eLearning, Niels W.C.J. van de Donk, 188656

Allogeneic stem cell transplantation: when and who ?

ESH eLearning, Shaji Kumar, 188655

Treatment of refractory disease

ESH eLearning, Meletios Dimopoulos, 188654

Treatment of high risk Multiple Myeloma: should we treat them differently ?

ESH eLearning, Philippe Moreau, 188653

First line treatment of Tx non-eligible patients from fit to frail

ESH eLearning, Sonja Zweegman, 188652

From limited to total: a back in the time of precision medicine

ESH eLearning, Bart Barlogie, 188651

CT ?

ESH eLearning, Elena Zamagni, 188650

MRD-based treatment paradigms: in minimal time ?

ESH eLearning, Angela Dispenzieri, 188649

Risk profiling in Multiple Myeloma: from cytogenetics to genomics

ESH eLearning, Hervé Avet-Loiseau, 188648

Newly diagnosed Multiple Myeloma: the role of looking different; from skeletal X-ray to CT, from Bence Jones to free light chains in plasma

ESH eLearning, Shaji Kumar, 188647

Molecular remission before alloSCT in Ph+ ALL: impact on relapse and long-term outcome

ESH eLearning, Arnon Nagler, 175147

Mutations in CLL and how they affect therapy choice (focus on NOTCH1, SF3B1, and TP53)

ESH eLearning, Gianluca Gaidano, 174310

Therapeutic targeting of biology in CLL: focus on signaling kinase and apoptosis modulation

ESH eLearning, Stephan Stilgenbauer, 174309

Treating anaemia according to patient genome

ESH eLearning, Eva Hellström- Lindberg, 174308

Personalized transplantation procedures in myeloid malignancies

ESH eLearning, Matteo Giovanni Della Porta, 174307

Implications of patient genome on clinical decision making in MDS/MPN

ESH eLearning, Michaela Fontenay, 174306

New subtypes of ALL

ESH eLearning, Charles Mullighan, 174303

The genomic landscape of ALL

ESH eLearning, Christine Harrison, 174302

Clinical significance of NGS in second-line treatment and beyond

ESH eLearning, Simona SOVERINI, 174301

Current status of standardization efforts for PCR in CML

ESH eLearning, Nick CROSS, 174300

CML monitoring: why, which, where and when?

ESH eLearning, Andreas Hochhaus, 174299

The future of JAK inhibition in MPN

ESH eLearning, Alessandro Vannucchi, 174298

Genotype-based clinical decision making in MPN

ESH eLearning, Francesco Passamonti, 174297

Next generation sequencing data analysis: critical issues

ESH eLearning, Torsten Haferlach, 174289

ABCs of genomics

ESH eLearning, Nick CROSS, 174287

Genomic applications in the clinic: are we ready?

ESH eLearning, Andreas Hochhaus, 174288

Translational implications of the medical genomics in AML

ESH eLearning, Torsten Haferlach, 174292

Genotype-tailored therapy of AML

ESH eLearning, Hartmut Döhner, 174293

Towards personalized medicine in AML

ESH eLearning, Bob Löwenberg, 174294

Precision medicine in AML: hope, hype or both?

ESH eLearning, Robert Gale, 174295

Elderly patient, first line

ESH eLearning, Simon Rule, 173819

Salvage treatment

ESH eLearning, Martin Dreyling, 173820

Pathology

ESH eLearning, Wolfram Klapper, 173818

Elderly patient, first line

ESH eLearning, Lorenz Trümper, 173817

Young patient, first line

ESH eLearning, F D'Amore, 173816

Pathology

ESH eLearning, Philippe Gaulard, 173815

CNS lymphoma

ESH eLearning, Andrés Ferreri, 173814

Plasmoblastic lymphoma

ESH eLearning, Miguel A Piris, 173813

Double hit lymphoma

ESH eLearning, H Tilly, 173812

Burkitt lymphoma

ESH eLearning, Vincent Ribrag, 173811

Salvage therapies

ESH eLearning, Michael Pfreundschuh, 173810

Transformed lymphoma

ESH eLearning, Wolfram Klapper, 173809

Role of PET

ESH eLearning, Olivier CASASNOVAS, 173808

Debate: In DLBCL, is cell of origin ready for prime time ?

ESH eLearning, Michael Pfreundschuh, 173807

R-CHOP and maintenance

ESH eLearning, Catherine Thieblemont, 173806

R-CHOP + targeted therapy

ESH eLearning, Andrew J. Davies, 173805

Optimized immunotherapy

ESH eLearning, Umberto Vitolo, 173804

Pathology ABC-GCB

ESH eLearning, Philippe Gaulard, 173803

Benefits and problems of allogeneic stem cell transplantation as multiple myeloma treatment

ESH eLearning, Nicolaus Kröger, 166044

New drugs and combinations in haematological cancers improve complete remission rates

ESH eLearning, Paolo Corradini, 166043

Overview of the CD38 antibody in multiple myeloma

ESH eLearning, Torben Plesner, 166042

Drug combos with daratumumab likely to become standard of care in myeloma

ESH eLearning, Niels Van De Donk, 166041

Preemptively treating patients most at risk of progression to myeloma

ESH eLearning, María-Victoria Mateos, 166040

How can we make the best decisions for health whilst considering cost?

ESH eLearning, Andrea Manca, 166039

Monoclonal antibodies in multiple myeloma

ESH eLearning, Phillippe Moreau, 166038

Cancer or amyloidosis?

ESH eLearning, Giovanni Palladini, 166037

Elderly patients should be treated based on biological age, not chronological

ESH eLearning, Heinz Ludwig, 166036

History of antiangiogenic drugs in multiple myeloma, starting with thalidomide

ESH eLearning, Jens Hillengaß, 166035

Better doctor-patient communication needed to improve myeloma outcomes

ESH eLearning, Karthik Ramasamy, 166034

Maintenance therapy in young myeloma patients beneficial after autologous stem cell transplant

ESH eLearning, Mohamad Mohty, 166033

History and progress of CD38 in myeloma

ESH eLearning, Fabio Malavasi, 166032

Overcoming painful bone disease in myeloma

ESH eLearning, Nicola Giuliani, 166031

Next generation MPN management

ESH eLearning, Ruben Mesa, 165442

Rethinking the treatment recommendations in low-risk PV

ESH eLearning, Tiziano Barbui, 165441

Natural history and risk stratification of prefibrotic myelofibrosis

ESH eLearning, Giovanni Barosi, 165440

The effects of specialized microenvironments on haematopoiesis in myelofibrosis

ESH eLearning, Ronald Hoffman, 165439

Using single cell biology to identify stem cell fate regulators in haematological malignancies

ESH eLearning, David Kent, 165438

Modeling predisposition to familial MPN

ESH eLearning, Isabelle Plo, 165437

Cellular and molecular response to interferon therapy in PV and ET

ESH eLearning, Josef Prchal, 165436

Targeting JAK2 – Have we arrived?

ESH eLearning, Thomas Radimerski, 165435

Molecular insights into regulation of JAK2 in MPN

ESH eLearning, Olli Silvennoinen, 165434

Role of megakaryocytes in the MPNs

ESH eLearning, John Crispino, 165433

Epigenetic alterations and therapeutic targeting in MPN

ESH eLearning, Ross Levine, 165432

The genomics of MPNs

ESH eLearning, Peter Campbell, 165431

The genomic basis of acute lymphoblastic leukaemia

ESH eLearning, Charles Mullighan, 165430

Causes of myeloproliferative disorders

ESH eLearning, Mary-Frances McMullin, 165429

Minimal residual disease

ESH eLearning, Bruno Paiva, 165481

Cytogenetics and NGS

ESH eLearning, Hervé Avet-Loiseau, 165480